Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kentaro Yamazaki

Showing results (41-50 of 252) with videos related to

Pageof 26
Sort By:
Pancreas|February 28, 2025
Efficacy of Neoadjuvant Therapy for Resectable Pancreatic Cancer Might be Limited to Biologically Borderline Resectable CasesYoshiyasu Kato, Ryo Ashida, Katsuhisa Ohgi, et al.
Investigational New Drugs|May 26, 2011
Phase I results from a two-part Phase I/II study of cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancerTaroh Satoh, Kensei Yamaguchi, Narikazu Boku, et al.
Clinical Colorectal Cancer|April 20, 2021
Real-World Evidence on Second-Line Treatment of Metastatic Colorectal Cancer Using Fluoropyrimidine, Irinotecan, and Angiogenesis InhibitorKentaro Yamazaki, Satoshi Yuki, Eiji Oki, et al.
International Journal of Clinical Oncology|February 28, 2012
Feasibility of mFOLFOX6 as the adjuvant treatment after curative resection of metastases from colorectal cancer in Japanese patientsNozomu Machida, Kouji Yoshizaki, Narikazu Boku, et al.
BMJ Open|October 2, 2012
Factors that prolong the 'postmortem interval until finding' (PMI-f) among community-dwelling elderly individuals in Japan: analysis of registration dataTomoko Ito, Nanako Tamiya, Hideto Takahashi, et al.
Forensic Science International|December 23, 2003
Non-traumatic postmortem computed tomographic (PMCT) findings of the lungSeiji Shiotani, Mototsugu Kohno, Noriyoshi Ohashi, et al.
Future Oncology (London, England)|June 30, 2023
Clinical outcomes of intensive versus less intensive first-line chemotherapy for metastatic colorectal cancerKentaro Yamazaki, Satoshi Yuki, Eiji Oki, et al.
BMC Cancer|June 14, 2020
Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology GroupKenro Hirata, Yasuo Hamamoto, Masahiko Ando, et al.
Cancer Science|March 8, 2017
Phase 1 study of OCV-C02, a peptide vaccine consisting of two peptide epitopes for refractory metastatic colorectal cancerHiroya Taniguchi, Satoru Iwasa, Kentaro Yamazaki, et al.
Journal of Cancer Research and Clinical Oncology|December 20, 2012
Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapyKohei Shitara, Satoshi Yuki, Kentaro Yamazaki, et al.
Pageof 26

Showing results (41-50 of 252) with videos related to

Sort By:
Pageof 26
Pancreas|February 28, 2025
Efficacy of Neoadjuvant Therapy for Resectable Pancreatic Cancer Might be Limited to Biologically Borderline Resectable CasesYoshiyasu Kato, Ryo Ashida, Katsuhisa Ohgi, et al.
Investigational New Drugs|May 26, 2011
Phase I results from a two-part Phase I/II study of cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancerTaroh Satoh, Kensei Yamaguchi, Narikazu Boku, et al.
Clinical Colorectal Cancer|April 20, 2021
Real-World Evidence on Second-Line Treatment of Metastatic Colorectal Cancer Using Fluoropyrimidine, Irinotecan, and Angiogenesis InhibitorKentaro Yamazaki, Satoshi Yuki, Eiji Oki, et al.
International Journal of Clinical Oncology|February 28, 2012
Feasibility of mFOLFOX6 as the adjuvant treatment after curative resection of metastases from colorectal cancer in Japanese patientsNozomu Machida, Kouji Yoshizaki, Narikazu Boku, et al.
BMJ Open|October 2, 2012
Factors that prolong the 'postmortem interval until finding' (PMI-f) among community-dwelling elderly individuals in Japan: analysis of registration dataTomoko Ito, Nanako Tamiya, Hideto Takahashi, et al.
Forensic Science International|December 23, 2003
Non-traumatic postmortem computed tomographic (PMCT) findings of the lungSeiji Shiotani, Mototsugu Kohno, Noriyoshi Ohashi, et al.
Future Oncology (London, England)|June 30, 2023
Clinical outcomes of intensive versus less intensive first-line chemotherapy for metastatic colorectal cancerKentaro Yamazaki, Satoshi Yuki, Eiji Oki, et al.
BMC Cancer|June 14, 2020
Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology GroupKenro Hirata, Yasuo Hamamoto, Masahiko Ando, et al.
Cancer Science|March 8, 2017
Phase 1 study of OCV-C02, a peptide vaccine consisting of two peptide epitopes for refractory metastatic colorectal cancerHiroya Taniguchi, Satoru Iwasa, Kentaro Yamazaki, et al.
Journal of Cancer Research and Clinical Oncology|December 20, 2012
Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapyKohei Shitara, Satoshi Yuki, Kentaro Yamazaki, et al.
Pageof 26